TCT 2025

Join us at TCT in San Francisco, October 25-28, to discover new waves of innovation and help us celebrate one million patients treated with Shockwave Intravascular Lithotripsy (IVL).

Wave After Wave of Innovation

Join us in San Francisco as we unveil the next era of Coronary IVL, plus exciting new safety data and a sneak peek at how we’re making even bigger waves as part of Johnson & Johnson MedTech.

  • Meet our next-generation Coronary IVL catheter and dive into the latest safety and efficacy data on our proven mechanism of action (MOA) at our expert-led symposium
  • Help us celebrate a shocking milestone — treating one million patients — at a special event featuring Dr. Nick West, Shockwave Medical CMO, and co-founder, John Adams
  • Continue your learning with scientific sessions of interest

Symposium | Introducing the Next Era of Coronary IVL: An Aero-volution in Calcium Modification

Sunday, October 26, 2025 | 12:30-1:30pm PT

Join us as we spark discussion and share findings that will energize your daily practice.

Learning objectives: 

  • Meet the newest device in our portfolio and see results from the first cases
  • Discover more about our unique MOA’s proven crack record
  • Explore pooled safety data from our Shockwave clinical studies, as well as EMPOWER CAD and BALI
Add to Calendar

Featured Shockwave Symposium Speakers

This section contains attributions including profile pictures, titles, descriptions, and Twitter handles.

  • Ziad Ali Headshot
    Dr. Ziad Ali, Moderator
    St Francis Hospital & Heart Center Roslyn, Roslyn, New York
  • Prof James Spratt Headshot
    Prof. James Spratt, Spokesperson
    St. George’s University NHS Trust, London, United Kingdom
  • Yousif Ahmad Headshot
    Dr. Yousif Ahmad, Spokesperson
    USCF Health, San Francisco, CA
  • Rhian Davies Headshot
    Dr. Rhian Davies, Spokesperson
    WellSpan Health, York, PA
  • Profile picture
    Dr. Matthew Price, Spokesperson
    Scripps Clinic, La Jolla, CA

Special Event | Teamwork Makes the Treatment Work: Thanks for Impacting the Lives of 1M Patients with IVL

Sunday, October 26, 2025 | Museum of Modern Art (MoMA) | 7:00pm – 9:30pm PT

Dr. Nick West, CMO of Shockwave Medical, and John Adams, co-founder of Shockwave Medical, reflect on our wave-making IVL journey from invention to treating one million patients worldwide.

Join us to commemorate this incredible milestone, recognize the physicians who made it possible, and look ahead at the innovations we’re developing now that will generate the future of IVL tomorrow.

RSVP

COSIRA II Clinical Trial

COSIRA II orange logoCOSIRA II is a multicenter, randomized, double-blind, sham-controlled trial designed to evaluate Shockwave Reducer, a novel therapeutic option for treating refractory angina pectoris. Learn more about this exciting trial, including target patients and participating sites in the U.S. and United Kingdom.1

Explore COSIRA II

Physicians featured are paid consultants of Shockwave Medical. 

Caution: In the United States, Shockwave Reducer is an investigational device, limited by United States law to investigational use. The Reducer is subject of Investigational testing and is being studied in the COSIRA-II trial in Canada. 

1 Shockwave Reducer is commercially available in certain countries outside the U.S. and Canada. Please contact your local representative for specific country availability. Prior to use, please reference the Instructions for Use for more information on warnings, precautions and adverse events: ifu.sw-reducer.com